Key facts
- It has raised $13.7M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Hefei Innovation Technology Venture Capital, Hefei Hi-Tech VC, Anhui Lianyuan Venture Capital, Nuoyan Capital, Anhui Guokong Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Precedo
- ·The full record, as it builds
Funding rounds
No funding rounds for Precedo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Precedo
Developer of targeted drugs designed for cancer treatment. The company focuses on the research and development of new targeted cancer drug relying on renewable cancer primary cell technology system and gene regulation engineering cell technology system, enabling advanced treatment for patients.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2015
- Website
- precedo.cn/
- Ownership
- Privately Held (backing)
Precedo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precedo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precedo in its N-PORT filings yet. We sweep new filings monthly.